CDE Clinical Trial Cost Calculator for Foreign Sponsors in China
Running clinical trials in China has become increasingly cost-effective relative to the US and Western Europe, but foreign sponsors (境外申办方, Jìngwài Shēnbànfāng) often struggle to budget accurately due to opaque pricing structures across contract research organizations (CROs), site fees, patient recruitment costs, and regulatory compliance expenses. The CDE Clinical Trial Cost Calculator provides a structured methodology for estimating total trial costs in China, broken down by therapeutic area, trial phase, site count, and patient enrollment targets.
Cost Components
A clinical trial in China involves eight primary cost categories. The table below shows average ranges based on data from 2024-2026 trial sponsor surveys and published CRO rate cards.
| Cost Category | Description | Phase I (RMB) | Phase II (RMB) | Phase III (RMB) |
|---|---|---|---|---|
| IND/CTA Filing | CDE submission fees + dossier preparation | 300K-800K | 400K-1M | 500K-1.2M |
| CRO Management | Full-service CRO (project management + monitoring) | 1M-3M | 3M-8M | 8M-20M |
| Site Fees | Hospital ethics committee + PI + research staff per site | 200K-500K/site | 300K-800K/site | 500K-1.5M/site |
| Patient Recruitment | Patient identification, screening, enrollment incentives | 50K-150K/subject | 30K-80K/subject | 20K-50K/subject |
| Laboratory/PK Testing | Central lab, biomarker analysis, PK/PD sample testing | 1M-3M | 2M-5M | 5M-15M |
| Data Management | EDC setup, data cleaning, biostatistics, CSR writing | 500K-1.5M | 1M-3M | 3M-8M |
| Regulatory Liaison | Pre-IND meetings, NDA preparation, CDE Q&A | 200K-500K | 500K-1M | 1M-3M |
| Insurance & Compliance | Clinical trial insurance, pharmacovigilance, audit | 100K-300K | 200K-500K | 300K-1M |
Cost Calculator by Therapeutic Area
Therapeutic area significantly impacts per-patient costs and overall trial budget. Oncology trials are the most expensive due to specialized monitoring and small patient pools, while vaccine and CNS trials have different cost drivers.
| Therapeutic Area | Cost per Patient (Phase III) | Typical Enrollment | Est. Total Phase III Cost |
|---|---|---|---|
| Oncology (solid tumors) | RMB 80K-150K | 300-600 | RMB 24M-90M |
| Oncology (hematology) | RMB 100K-200K | 150-300 | RMB 15M-60M |
| Cardiovascular | RMB 30K-60K | 500-2,000 | RMB 15M-120M |
| CNS (Alzheimer’s) | RMB 60K-120K | 300-1,000 | RMB 18M-120M |
| Infectious Disease (vaccine) | RMB 15K-40K | 1,000-5,000 | RMB 15M-200M |
| Rare Disease | RMB 200K-400K | 30-100 | RMB 6M-40M |
| Autoimmune | RMB 40K-80K | 200-500 | RMB 8M-40M |
Step-by-Step Calculator Usage
Step 1: Determine Trial Phase and Patient Count
Start with your clinical development plan. For a typical oncology Phase III trial enrolling 400 patients across 15 sites:
- Total patients: 400
- Number of sites: 15
- Patients per site: ~27
Step 2: Calculate Per-Patient Cost
Using oncology solid tumor rates: RMB 100K/patient (mid-range). Total patient cost: 400 × RMB 100K = RMB 40M.
Step 3: Add Site and CRO Costs
15 sites × RMB 800K/site (mid-range Phase III) = RMB 12M. Full-service CRO: RMB 14M (mid-range).
Step 4: Add Centralized Services
Central lab + data management + regulatory liaison + insurance: RMB 12M (mid-range estimate).
Step 5: Total Estimated Budget
RMB 78M (approximately USD 10.8M) — compared to USD 40-60M for the same trial in the US, representing a 60-75% cost saving.
China vs. Global Cost Comparison
| Component | China | United States | Western Europe | China Savings |
|---|---|---|---|---|
| Per-patient cost (oncology Phase III) | RMB 80K-150K | USD 50K-100K | USD 30K-60K | 70-80% |
| CRO management (Phase III, 3-year) | RMB 8M-20M | USD 5M-15M | USD 3M-10M | 60-75% |
| Site initiation to FPFS time | 2-4 months | 6-12 months | 4-8 months | 40-60% faster |
| Patient recruitment (oncology, 400 pts) | 6-12 months | 12-24 months | 12-18 months | 40-60% faster |
Key Pitfalls
Next Steps
- Request CRO bids — Solicit itemized proposals from at least 3 China-based CROs (e.g., Tigermed, WuXi AppTec, Hangzhou Tigermed) using the cost categories above.
- Select trial sites — Prioritize CDE-certified GCP sites (GCP认证, GCP rènzhèng) in Beijing, Shanghai, and Guangzhou — these have faster ethics review turnaround (30-45 days vs. 60-90 days at provincial sites).
- File pre-IND — Submit a CDE pre-IND meeting request to confirm trial design and primary endpoint acceptability, which can reduce protocol amendment costs by 20-30%.
- Budget with buffers — Add a 20% contingency to the calculated total for protocol amendments, site additions, and currency fluctuation.
A well-budgeted China clinical trial typically delivers 50-70% cost savings compared to the US, with faster enrollment timelines that can shorten overall development time by 12-18 months. Foreign sponsors should budget RMB 50-150M (USD 7-21M) for a full Phase III program in China depending on therapeutic area.
— China Gateway 360 —
Your trusted source for foreign business intelligence in China.
